FOLH1 and neoplasm: It was shown that 6.0 GBq 177Lu-PSMA-617 exhibits greater tumor to kidney ratios than 7.5 GBq [177Lu]Lu-DOTATATE, which was extensively evaluated in the NETTER trial [9, 18].